Cargando…

Docetaxel population pharmacokinetic modelling and simulation in Chinese cancer patients

BACKGROUND: Docetaxel is a widely prescribed cytotoxic chemotherapy drug for various cancers and the main dose-limiting toxicity is dose-dependent neutropenia. In China, the current dose regimen for docetaxel frequently results in high inter-individual pharmacokinetic (PK) variability. There is a ve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Jian, Zhang, Yuwen, Li, Ze, Li, Xingang, Zhao, Chenglong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279759/ https://www.ncbi.nlm.nih.gov/pubmed/35845493 http://dx.doi.org/10.21037/atm-22-2619

Ejemplares similares

Clinical pharmacokinetics and drug exposure-toxicity correlation study of docetaxel based chemotherapy in Chinese head and neck cancer patients
por: Ma, Yuxiang, et al.
Publicado: (2020)

ADME gene polymorphisms do not influence the pharmacokinetics of docetaxel: Results from a population pharmacokinetic study in Indian cancer patients
por: Patil, Anand, et al.
Publicado: (2021)

Assessment of the Utility of Physiologically-based Pharmacokinetic Model for prediction of Pharmacokinetics in Chinese and Japanese Populations
por: Yu, Yanke, et al.
Publicado: (2021)

The Population Pharmacokinetic Models of Tacrolimus in Chinese Adult Liver Transplantation Patients
por: Zhu, Liqin, et al.
Publicado: (2014)

Clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer
por: Lin, Guo-Wen, et al.
Publicado: (2019)

Population pharmacokinetic modeling of flurbiprofen, the active metabolite of flurbiprofen axetil, in Chinese patients with postoperative pain
por: Zhang, Jingru, et al.
Publicado: (2018)

Development of a population pharmacokinetic model of olanzapine for Chinese health volunteers and patients with schizophrenia
por: Li, Anning, et al.
Publicado: (2018)

Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report
por: Yang, Liu, et al.
Publicado: (2015)

Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy
por: Fr Brunsvig, Paal, et al.
Publicado: (2007)

Population Pharmacokinetic Modeling and Dose Optimization of Vancomycin in Chinese Patients with Augmented Renal Clearance
por: Zhao, Sixuan, et al.
Publicado: (2021)

Population pharmacokinetics of peginterferon α2a in patients with chronic hepatitis B
por: Bi, Jingfeng, et al.
Publicado: (2017)

Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study
por: Syn, Nicholas Li‐Xun, et al.
Publicado: (2016)

Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non‐small cell lung cancer
por: Heineman, Thomas, et al.
Publicado: (2021)

Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
por: Vermunt, Marit A. C., et al.
Publicado: (2022)

Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine
por: Fiedler‐Kelly, Jill B., et al.
Publicado: (2019)

Pharmacokinetics and Safety of Vortioxetine in the Chinese Population
por: Miao, Jia, et al.
Publicado: (2019)

Effect of the Phragmitis rhizoma Aqueous Extract on the Pharmacokinetics of Docetaxel in Rats
por: Shin, Sarah, et al.
Publicado: (2019)

Population pharmacokinetics and dosing optimization of unbound teicoplanin in Chinese adult patients
por: Fu, Wen-Qian, et al.
Publicado: (2022)

Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients
por: Wang, Zhiqi, et al.
Publicado: (2019)

Population pharmacokinetic modeling and clinical application of vancomycin in Chinese patients hospitalized in intensive care units
por: Lin, Zhong, et al.
Publicado: (2021)

Population pharmacokinetics and dosing optimization of metformin in Chinese patients with type 2 diabetes mellitus
por: Li, Ling, et al.
Publicado: (2020)

Population Pharmacokinetics of Cyclosporine in Chinese Pediatric Patients With Acquired Aplastic Anemia
por: Gao, Xuan, et al.
Publicado: (2022)

Population pharmacokinetic model of vancomycin in postoperative neurosurgical patients
por: Wei, Shifeng, et al.
Publicado: (2022)

Bioequivalence and Population Pharmacokinetic Modeling of Two Forms of Antibiotic, Cefuroxime Lysine and Cefuroxime Sodium, after Intravenous Infusion in Beagle Dogs
por: Zhao, Longshan, et al.
Publicado: (2012)

Drug-Virus Interaction: Effect of Administration of Recombinant Adenoviruses on the Pharmacokinetics of Docetaxel in a Rat Model
por: Wonganan, Piyanuch, et al.
Publicado: (2008)

Development of a Population Pharmacokinetic Model of Vancomycin and its Application in Chinese Geriatric Patients with Pulmonary Infections
por: Zhou, Ying, et al.
Publicado: (2018)

Translational Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Oxaliplatin and Irinotecan in Colorectal Cancer
por: Zhu, Jinwei, et al.
Publicado: (2023)

Pharmacokinetics and Safety of Doripenem in Healthy Chinese Subjects and Monte Carlo Dosing Simulations
por: Wang, Yu, et al.
Publicado: (2022)

Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients
por: Fajac, A, et al.
Publicado: (2010)

Population pharmacokinetics model for escitalopram in Chinese psychiatric patients: effect of CYP2C19 and age
por: Liu, Shujing, et al.
Publicado: (2022)

Population Pharmacokinetics Modeling of Vancomycin Among Chinese Infants With Normal and Augmented Renal Function
por: Li, De-Yi, et al.
Publicado: (2021)

Therapeutic drug monitoring of docetaxel by pharmacokinetics and pharmacogenetics: A randomized clinical trial of AUC‐guided dosing in nonsmall cell lung cancer
por: Ma, Yuxiang, et al.
Publicado: (2021)

Population pharmacokinetics and exposure–response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia
por: Kuchimanchi, Mita, et al.
Publicado: (2018)

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours
por: Pronk, L C, et al.
Publicado: (2000)

Intravenous microemulsion of docetaxel containing an anti-tumor synergistic ingredient (Brucea javanica oil): formulation and pharmacokinetics
por: Ma, Shilin, et al.
Publicado: (2013)

Development of a physiologically based pharmacokinetic (PBPK) population model for Chinese elderly subjects
por: Cui, Cheng, et al.
Publicado: (2021)

Population Pharmacokinetic Modeling and Simulation of TQ-B3101 to Inform Dosing in Pediatric Patients With Solid Tumors
por: Yang, Fen, et al.
Publicado: (2022)

Docetaxel versus docetaxel plus cisplatin for non-small-cell lung cancer: a meta-analysis of randomized clinical trials
por: Li, Ang, et al.
Publicado: (2017)

Pharmacokinetics of immediate and sustained-release formulations of paroxetine: Population pharmacokinetic approach to guide paroxetine personalized therapy in chinese psychotic patients
por: Li, Xiao-lin, et al.
Publicado: (2022)

Pharmacokinetics and in vitro/in vivo antitumor efficacy of aptamer-targeted Ecoflex(®) nanoparticles for docetaxel delivery in ovarian cancer
por: Ghassami, Erfaneh, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gojlqv2t66m4a1bnu4k9if67co